Ozempic isn’t the only drug that mimics the natural GLP-1 hormone, so users feel fuller for longer and eat less. There’s also Zepbound, Mounjaro, Trulicity and Victoza — and many more on the horizon ...

Biosimilar Ondibta ® (insulin glargine) approved for treatment of diabetes mellitus across all indications of reference medicine Expected launch by early 2027; potential to expand access to insulin ...

Switzerland-based Sandoz (SIX: SDZ), a global leader in affordable medicines, today confirmed that the European Commission has granted marketing authorization for Ondibta insulin glargine), a solution ...

Add Yahoo as a preferred source to see more of our stories on Google. Medtronic said Monday it received 510(k) clearance from the Food and Drug Administration for an app to connect its smart insulin ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min According to the DOJ, CVS ...

CVS has agreed to pay almost $38 million to settle allegations that its pharmacies overcharged the government for insulin pens over a decade, putting to bed a Department of Justice lawsuit and several ...

CVS Health (CVS) has reached a settlement with the U.S. government, requiring the company to pay $37.76M to resolve claims that it overbilled government healthcare programs for insulin pens. The ...

NEW YORK, Dec 2 (Reuters) - CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements from Medicare, ‌Medicaid ...

CVS Health agreed to pay $37.76 million to settle allegations that it dispensed too many insulin pens to patients and improperly billed federal healthcare programs for those insulin prescriptions. The ...